TP53-mutated ALL: hyper-CVAD negates effect of mutation on outcomes

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Patients with adult B-cell immunophenotype acute lymphoblastic leukemia (ALL) and tumor protein 53 (TP53) mutations have poor prognosis; treatment with hyper-CVAD-based (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimens appears to overcome the prognostic effect of TP53 mutations.

Why this matters

  • TP53 mutation is associated with inferior outcomes in ALL.

Study design

  • Study to investigate an association between the presence of TP53 mutations and outcomes in 164 patients with newly diagnosed ALL treated with hyper-CVAD regimens.
  • Data was sourced for appropriate patients were treated at a single institution between 2012 and 2016.
  • Funding: National Institutes of Health/National Cancer Institute, Charif Souki Cancer Research Fund.

Key results

  • 15% had a TP53 mutation.
  • A significant ...